Physician profile
Chenna B Reddy
NPI 1679640650
$7,949.73
in general payments reported to CMS, 2019-2025
28 companies · $974 in 2025
The $974 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $939 · 2021: $1,120 · 2022: $1,318 · 2023: $1,169 · 2024: $911 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,053.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,776.14 | 2021-2025 | |
| Medtronic, INC. | $1,138.20 | 2021-2024 | Hawkone |
| Lilly USA, LLC | $636.18 | 2019-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $610.16 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $603.31 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bard Peripheral Vascular, INC. | $499.82 | 2023-2025 | Lutonix Drug Coated Balloon, Rotarexs 6 F X 135 Cm, Crosser Iq |
| Novo Nordisk INC | $408.36 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $345.31 | 2019-2022 | |
| Pfizer INC. | $240.73 | 2019-2020 | |
| Abbott Laboratories | $190.64 | 2020 | |
| Janssen Pharmaceuticals, INC | $179.38 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.51 | 2019 | |
| Shockwave Medical, INC | $154.91 | 2021 | |
| Optinose US, INC. | $125.00 | 2021 | |
| Amgen INC. | $118.45 | 2019-2024 | Repatha, Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $110.52 | 2025 | Austedo Xr, Uzedy |
| Mannkind Corporation | $100.59 | 2019-2022 | |
| Abbvie INC. | $99.78 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $91.37 | 2022 | |
| Exact Sciences Corporation | $78.40 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $70.25 | 2024-2025 | Zoryve |
| Lundbeck LLC | $47.88 | 2025 | Rexulti |
| Arbor Pharmaceuticals, INC. | $47.26 | 2019-2020 | |
| Glaxosmithkline, LLC. | $42.99 | 2023-2024 | Shingrix |
| Phadia US INC. | $23.22 | 2019 | |
| Genentech USA, INC. | $19.50 | 2019 | |
| Shield Therapeutics INC | $19.19 | 2023 | Accrufer |
| Medtronic Minimed, INC. | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chenna Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.